ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2026
Tissue eosinophilia suggests dupilumab treatment response in chronic rhinosinusitis with nasal polyps (CRSwNP).
Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic rhinosinusitis with nasal polyps (CRSwNP) is predominantly driven by type 2 inflammation and frequently persists despite standard therapy. Dupilumab has proven efficacy, yet robust predictors of long-term response remain insufficiently defined.
methodsIn this monocentric, retrospective analysis, 163 adults with CRSwNP treated with dupilumab for ≥ 24 months were assessed at a tertiary referral center. Outcome parameters included nasal polyp score (NPS), sinonasal quality of life (SNOT-22), and olfactory function (SSIT). Treatment response was classified according to EUFOREA 2023 criteria. Archived polyp tissue from 72 patients obtained prior to Dupilumab treatment underwent histological reassessment, with eosinophilic infiltration quantified using absolute thresholds (Lee et al.: ≤10, 11–69, ≥ 70 eosinophils/HPF) and relative thresholds (Yang et al.: >20%).
resultsDupilumab led to marked and sustained clinical improvements across the cohort (NPS − 4.6 ± 2.1; SNOT-22 − 44.1 ± 18.5; SSIT + 4.3 ± 2.9 at 24 months). Outcomes were independent of demographic factors, asthma, NERD, allergen sensitization, serum IgE, or blood eosinophils. In contrast, higher tissue eosinophilia correlated with enhanced short-term responses. Patients with > 20% eosinophils showed significantly greater SNOT-22 reduction at 12 months (p < 0.05). Stratification by ≥ 70 eosinophils/HPF and Yang’s classification (0–10, 11–69, ≥ 70) consistently showed superior trajectories in high-grade eosinophilia. EUFOREA response rates were highest in these subgroups, with no non-responders observed.
conclusionDupilumab achieved durable benefit across all patient subgroups, while elevated tissue eosinophilia predicted faster and more pronounced short-term improvements. Systematic eosinophil quantification may refine patient stratification and optimize biologic therapy allocation in CRSwNP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.